Blue Trust Inc. Purchases 371 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Blue Trust Inc. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 100.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 742 shares of the company’s stock after buying an additional 371 shares during the quarter. Blue Trust Inc.’s holdings in Vaxcyte were worth $61,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Meeder Asset Management Inc. increased its holdings in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. bought a new position in shares of Vaxcyte in the third quarter worth about $92,000. Signaturefd LLC raised its stake in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after acquiring an additional 358 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Vaxcyte by 21.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company’s stock valued at $220,000 after buying an additional 475 shares during the period. Finally, MML Investors Services LLC purchased a new stake in shares of Vaxcyte in the 3rd quarter worth approximately $260,000. 96.78% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at $19,024,730.55. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the completion of the transaction, the chief executive officer now owns 450,301 shares in the company, valued at approximately $41,630,327.45. This represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,616 shares of company stock worth $6,766,481 in the last ninety days. 3.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PCVX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of Vaxcyte in a report on Tuesday, February 11th. Finally, The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $127.71.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $81.68 on Tuesday. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06. The stock has a market cap of $10.18 billion, a P/E ratio of -17.76 and a beta of 0.98. The stock’s 50 day simple moving average is $85.46 and its 200-day simple moving average is $94.99.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.